Header Logo
Last Name

Michelle C Callegan

InstitutionUniversity of Oklahoma Health Sciences Center
Address608 Stanton L Young Blvd
Oklahoma City OK 73104-5014
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    F32EY006813     (CALLEGAN, MICHELLE C)Aug 10, 1997
    Role: Principal Investigator

    R01EY012985     (CALLEGAN, MICHELLE C)Jun 1, 2000 - Aug 31, 2014
    Mechanisms of Inflammation and Vision Loss in Endophthalmitis
    Role: Principal Investigator

    R21EY022466     (CALLEGAN, MICHELLE C)Dec 1, 2012 - Nov 30, 2015
    New Models of Endogenous Bacterial Endophthalmitis
    Role: Principal Investigator

    R01EY024140     (CALLEGAN, MICHELLE C)Jan 1, 2014 - Dec 31, 2017
    Vascular Permeability and Ocular Infections
    Role: Principal Investigator

    R01EY025947     (CALLEGAN, MICHELLE C)Sep 30, 2015 - Aug 31, 2018
    Nanotherapeutics for Ocular Infections
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Callegan MC, Parkunan SM, Randall CB, Coburn PS, Miller FC, LaGrow AL, Astley RA, Land C, Oh SY, Schneewind O. The role of pili in Bacillus cereus intraocular infection. Exp Eye Res. 2017 Jun; 159:69-76. PMID: 28336259.
      View in: PubMed
    2. Parkunan SM, Randall CB, Astley RA, Furtado GC, Lira SA, Callegan MC. CXCL1, but not IL-6, significantly impacts intraocular inflammation during infection. J Leukoc Biol. 2016 Nov; 100(5):1125-1134. PMID: 27286792.
      View in: PubMed
    3. Coburn PS, Wiskur BJ, Miller FC, LaGrow AL, Astley RA, Elliott MH, Callegan MC. Bloodstream-To-Eye Infections Are Facilitated by Outer Blood-Retinal Barrier Dysfunction. PLoS One. 2016; 11(5):e0154560. PMID: 27195776; PMCID: PMC4873292.
    4. Astley RA, Coburn PS, Parkunan SM, Callegan MC. Modeling intraocular bacterial infections. Prog Retin Eye Res. 2016 Sep; 54:30-48. PMID: 27154427; PMCID: PMC4992594 [Available on 09/01/17].
    5. Venincasa VD, Callegan M, Astley RA, Siatkowski RM. Contact Lens-related Polymicrobial Keratitis from Pantoea agglomerans and Escherichia vulneris. Am J Ophthalmol Case Rep. 2016 Apr; 1:5-7. PMID: 27158679.
      View in: PubMed
    6. Coburn PS, Wiskur BJ, Astley RA, Callegan MC. Blood-Retinal Barrier Compromise and Endogenous Staphylococcus aureus Endophthalmitis. Invest Ophthalmol Vis Sci. 2015 Nov; 56(12):7303-11. PMID: 26559476; PMCID: PMC4642607.
    7. Parkunan SM, Randall CB, Coburn PS, Astley RA, Staats RL, Callegan MC. Unexpected Roles for Toll-Like Receptor 4 and TRIF in Intraocular Infection with Gram-Positive Bacteria. Infect Immun. 2015 Oct; 83(10):3926-36. PMID: 26195555; PMCID: PMC4567632.
    8. Li X, Gu X, Boyce TM, Zheng M, Reagan AM, Qi H, Mandal N, Cohen AW, Callegan MC, Carr DJ, Elliott MH. Caveolin-1 increases proinflammatory chemoattractants and blood-retinal barrier breakdown but decreases leukocyte recruitment in inflammation. Invest Ophthalmol Vis Sci. 2014 Aug 26; 55(10):6224-34. PMID: 25159208; PMCID: PMC4183075.
    9. Parkunan SM, Astley R, Callegan MC. Role of TLR5 and flagella in bacillus intraocular infection. PLoS One. 2014; 9(6):e100543. PMID: 24959742; PMCID: PMC4068998.
    10. Hunt JJ, Astley R, Wheatley N, Wang JT, Callegan MC. TLR4 contributes to the host response to Klebsiella intraocular infection. Curr Eye Res. 2014 Aug; 39(8):790-802. PMID: 24588082; PMCID: PMC4144821.
    11. Pettey JH, Mifflin MD, Kamae K, McEntire MW, Pettey DH, Callegan MC, Brown H, Olson RJ. The impact of short-term topical gatifloxacin and moxifloxacin on bacterial injection after hypodermic needle passage through human conjunctiva. J Ocul Pharmacol Ther. 2013 Jun; 29(5):450-5. PMID: 23425429.
      View in: PubMed
    12. Coburn PS, Wiskur BJ, Christy E, Callegan MC. The diabetic ocular environment facilitates the development of endogenous bacterial endophthalmitis. Invest Ophthalmol Vis Sci. 2012 Nov 01; 53(12):7426-31. PMID: 23036996; PMCID: PMC3487485.
    13. Callegan M, Gregory-Ksander M, Willcox M, Lightman S. Ocular inflammation and infection. Int J Inflam. 2012; 2012:403520. PMID: 23091771; PMCID: PMC3471427.
    14. Novosad BD, Astley RA, Callegan MC. Role of Toll-like receptor (TLR) 2 in experimental Bacillus cereus endophthalmitis. PLoS One. 2011; 6(12):e28619. PMID: 22163046; PMCID: PMC3232239.
    15. Callegan MC, Guess S, Wheatley NR, Woods DC, Griffin G, Wiskur BJ, Leonard R. Efficacy of vitrectomy in improving the outcome of Bacillus cereus endophthalmitis. Retina. 2011 Sep; 31(8):1518-24. PMID: 21606892; PMCID: PMC4505805.
    16. Hunt JJ, Wang JT, Callegan MC. Contribution of mucoviscosity-associated gene A (magA) to virulence in experimental Klebsiella pneumoniae endophthalmitis. Invest Ophthalmol Vis Sci. 2011 Aug 29; 52(9):6860-6. PMID: 21791595; PMCID: PMC3176006.
    17. Olson R, Donnenfeld E, Bucci FA, Price FW, Raizman M, Solomon K, Devgan U, Trattler W, Dell S, Wallace RB, Callegan M, Brown H, McDonnell PJ, Conway T, Schiffman RM, Hollander DA. Methicillin resistance of Staphylococcus species among health care and nonhealth care workers undergoing cataract surgery. Clin Ophthalmol. 2010 Dec 10; 4:1505-14. PMID: 21191448; PMCID: PMC3009999.
    18. Novosad BD, Callegan MC. Severe bacterial endophthalmitis: towards improving clinical outcomes. Expert Rev Ophthalmol. 2010 Oct; 5(5):689-698. PMID: 21572565.
      View in: PubMed
    19. Callegan MC. Checks and balances: the ocular response to infection. Virulence. 2010 Jul-Aug; 1(4):222. PMID: 21178447; PMCID: PMC3073293.
    20. Callegan MC, Novosad BD, Ramadan RT, Wiskur B, Moyer AL. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones. Adv Ther. 2009 Apr; 26(4):447-54. PMID: 19381523.
      View in: PubMed
    21. Moyer AL, Ramadan RT, Novosad BD, Astley R, Callegan MC. Bacillus cereus-induced permeability of the blood-ocular barrier during experimental endophthalmitis. Invest Ophthalmol Vis Sci. 2009 Aug; 50(8):3783-93. PMID: 19264886; PMCID: PMC2880527.
    22. Rajala RV, Wiskur B, Tanito M, Callegan M, Rajala A. Diabetes reduces autophosphorylation of retinal insulin receptor and increases protein-tyrosine phosphatase-1B activity. Invest Ophthalmol Vis Sci. 2009 Mar; 50(3):1033-40. PMID: 19029027; PMCID: PMC2694133.
    23. Wiskur BJ, Hunt JJ, Callegan MC. Hypermucoviscosity as a virulence factor in experimental Klebsiella pneumoniae endophthalmitis. Invest Ophthalmol Vis Sci. 2008 Nov; 49(11):4931-8. PMID: 18586871; PMCID: PMC2576484.
    24. Ramadan RT, Moyer AL, Callegan MC. A role for tumor necrosis factor-alpha in experimental Bacillus cereus endophthalmitis pathogenesis. Invest Ophthalmol Vis Sci. 2008 Oct; 49(10):4482-9. PMID: 18586878; PMCID: PMC2574773.
    25. Wiskur BJ, Robinson ML, Farrand AJ, Novosad BD, Callegan MC. Toward improving therapeutic regimens for Bacillus endophthalmitis. Invest Ophthalmol Vis Sci. 2008 Apr; 49(4):1480-7. PMID: 18385066; PMCID: PMC2531288.
    26. Charles E, Callegan MC, Blader IJ. The SAG1 Toxoplasma gondii surface protein is not required for acute ocular toxoplasmosis in mice. Infect Immun. 2007 Apr; 75(4):2079-83. PMID: 17283084; PMCID: PMC1865684.
    27. Callegan MC, Gilmore MS, Gregory M, Ramadan RT, Wiskur BJ, Moyer AL, Hunt JJ, Novosad BD. Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions. Prog Retin Eye Res. 2007 Mar; 26(2):189-203. PMID: 17236804; PMCID: PMC1941835.
    28. Gregory M, Callegan MC, Gilmore MS. Role of bacterial and host factors in infectious endophthalmitis. Chem Immunol Allergy. 2007; 92:266-75. PMID: 17264502.
      View in: PubMed
    29. Ramadan RT, Ramirez R, Novosad BD, Callegan MC. Acute inflammation and loss of retinal architecture and function during experimental Bacillus endophthalmitis. Curr Eye Res. 2006 Nov; 31(11):955-65. PMID: 17114121.
      View in: PubMed
    30. Callegan MC, Novosad BD, Ramirez R, Ghelardi E, Senesi S. Role of swarming migration in the pathogenesis of bacillus endophthalmitis. Invest Ophthalmol Vis Sci. 2006 Oct; 47(10):4461-7. PMID: 17003440.
      View in: PubMed
    31. Callegan MC, Cochran DC, Kane ST, Ramadan RT, Chodosh J, McLean C, Stroman DW. Virulence factor profiles and antimicrobial susceptibilities of ocular bacillus isolates. Curr Eye Res. 2006 Sep; 31(9):693-702. PMID: 16966141.
      View in: PubMed
    32. Callegan MC, Kane ST, Cochran DC, Novosad B, Gilmore MS, Gominet M, Lereclus D. Bacillus endophthalmitis: roles of bacterial toxins and motility during infection. Invest Ophthalmol Vis Sci. 2005 Sep; 46(9):3233-8. PMID: 16123424.
      View in: PubMed
    33. Callegan MC, Ramirez R, Kane ST, Cochran DC, Jensen H. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv Ther. 2003 Sep-Oct; 20(5):246-52. PMID: 14964344.
      View in: PubMed
    34. Callegan MC, Kane ST, Cochran DC, Gilmore MS, Gominet M, Lereclus D. Relationship of plcR-regulated factors to Bacillus endophthalmitis virulence. Infect Immun. 2003 Jun; 71(6):3116-24. PMID: 12761089; PMCID: PMC155772.
    35. Callegan MC, Cochran DC, Kane ST, Gilmore MS, Gominet M, Lereclus D. Contribution of membrane-damaging toxins to Bacillus endophthalmitis pathogenesis. Infect Immun. 2002 Oct; 70(10):5381-9. PMID: 12228262; PMCID: PMC128340.
    36. Callegan MC, Kane ST, Cochran DC, Gilmore MS. Molecular mechanisms of Bacillus endophthalmitis pathogenesis. DNA Cell Biol. 2002 May-Jun; 21(5-6):367-73. PMID: 12167238.
      View in: PubMed
    37. Ruan X, Chodosh J, Callegan MC, Booth MC, Lee TD, Kumar P, Gilmore MS, Pereira HA. Corneal expression of the inflammatory mediator CAP37. Invest Ophthalmol Vis Sci. 2002 May; 43(5):1414-21. PMID: 11980855.
      View in: PubMed
    38. Callegan MC, Engelbert M, Parke DW, Jett BD, Gilmore MS. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev. 2002 Jan; 15(1):111-24. PMID: 11781270; PMCID: PMC118063.
    39. Callegan MC, Booth MC, Gilmore MS. In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens. Cornea. 2000 Jul; 19(4):539-45. PMID: 10928774.
      View in: PubMed
    Callegan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description
    Physical Neighbors Expand Description